BIODESIX INC (BDSX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-02

Key Insights

Insider John Patience, the Chairman, acquired 1,361 shares of Biodesix Inc. (BDSX) through the vesting of restricted stock units on March 31, 2026.
Patience also holds significant indirect beneficial ownership of Biodesix's common stock through Patience Enterprises LP and the John Patience Living Trust, indicating his sizable stake in the company.
The restricted stock units vest in four equal installments throughout 2026, suggesting Patience's continued commitment to Biodesix's long-term success.

Want the newest filings?

This analysis covers the filing from 2026-04-02. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-27

Jack W. Schuler, an Emeritus Director of BIODESIX INC, has been actively purchasing the company's stock, acquiring a total of 100,000 shares in two separate transactions at weighted average prices of $11.8084 and $11.8032.
Schuler's purchases have increased his total beneficial ownership in the company, with 1,563,210 shares held directly through the Jack W. Schuler Living Trust and an additional 750,000 shares held indirectly through the Jack W. Schuler 2025 GRAT.
The reported transactions suggest Schuler's confidence in the company's prospects and potential future growth, which could be a positive signal for other investors.

Filed: 2026-01-26

Jack W. Schuler, an Emeritus Director of BIODESIX INC, acquired 82,465 shares of the company's common stock on January 22, 2026 at a weighted average price of $10.9569 per share.
In addition to the direct share acquisition, Schuler also holds an indirect beneficial ownership of 1,463,210 shares through the Jack W. Schuler Living Trust and 750,000 shares through the Jack W. Schuler 2025 GRAT.
Insider buying, especially by a director, can be a positive signal for investors as it indicates confidence in the company's prospects.

Filed: 2026-01-20

Chris Vazquez, the Chief Accounting Officer of BIODESIX INC, acquired 219 shares of common stock through the vesting of restricted stock units (RSUs) on January 15, 2026.
Vazquez then sold 83 shares on January 16, 2026 at a weighted average price of $8.1493 to cover taxes, leaving him with a direct ownership of 1,072 shares.
The transactions were part of a planned sale arrangement under Rule 10b5-1, indicating a systematic approach to managing equity compensation.

Filed: 2026-01-20

The Chief Development Officer, Gary Pestano, exercised 805 restricted stock units (RSUs) and sold 298 shares to cover taxes, indicating ongoing insider engagement and alignment with the company's performance.
The reported transactions represent a relatively small portion of Pestano's total beneficial ownership, which remains at 8,446 shares following the reported transactions.
The sale price of $8.15 per share is within a reasonable range, suggesting the transactions were conducted in the normal course of business.

Filed: 2026-01-20

Kieran O'Kane, the Chief Commercial Officer of Biodesix Inc., exercised 805 restricted stock units and sold 298 shares to cover taxes, indicating ongoing insider activity.
The shares were sold at a weighted average price of $8.1493, which could provide insight into the current market valuation of the company's stock.
The transaction was conducted pursuant to a Rule 10b5-1 trading plan, suggesting a pre-determined strategy for insider selling.

Filed: 2026-01-20

Scott Hutton, the President and CEO of Biodesix Inc., acquired 2,633 shares of the company's common stock through the vesting of restricted stock units (RSUs), and subsequently sold 970 shares to cover taxes.
Hutton's total beneficial ownership of Biodesix shares decreased from 39,944 to 38,974 shares as a result of the reported transactions.
The sale of shares to cover taxes is a common practice for executives receiving equity compensation, and the overall reduction in Hutton's ownership is relatively small, suggesting no major changes in his investment in the company.

Filed: 2026-01-20

The reporting person, Robin Harper Cowie, is the CFO, Secretary, and Treasurer of BIODESIX INC (BDSX), indicating their significant role and insider status within the company.
Cowie exercised 805 restricted stock units (RSUs) on January 15, 2026, and subsequently sold 298 shares to cover taxes, suggesting ongoing equity compensation and insider activity.
The reported transactions occurred after a 1-for-20 reverse stock split in September 2025, which should be considered when analyzing the share amounts and prices.

Filed: 2026-01-06

Jean M. Franchi, a director of BIODESIX INC, has received a grant of 8,164 restricted stock units (RSUs) and 6,354 stock options, vesting over 2026.
The RSUs and stock options represent a significant grant of equity compensation to Franchi, potentially aligning her interests with those of the company and its shareholders.
The timing and size of the equity award suggests the company may be seeking to incentivize and retain Franchi's service on the board of directors.

Filed: 2026-01-06

Chris Vazquez, the Chief Accounting Officer of BIODESIX INC, has been granted a stock option to acquire 12,000 shares of the company's common stock, which vests over a 4-year period.
The option has an exercise price of $6.46 per share, which suggests the grant is intended to incentivize Vazquez to drive the company's growth and create shareholder value.
Insider transactions, such as this option grant, can provide insight into management's confidence in the company's future prospects and their alignment with shareholder interests.

Filed: 2026-01-06

Matthew Strobeck, a director of BIODESIX INC (BDSX), acquired 6,804 restricted stock units and 6,354 stock options on January 2, 2026, suggesting continued management confidence in the company's future.
The restricted stock units and stock options vest over the course of 2026, indicating that Strobeck's compensation is tied to the company's long-term performance.
The insider acquisition represents a significant amount of equity, suggesting that Strobeck believes BIODESIX's shares are undervalued and that the company has strong growth potential.

Filed: 2026-01-06

The reporting person, John Patience, is the Chairman of Biodesix Inc (BDSX) and has significant beneficial ownership in the company through direct and indirect holdings.
Patience exercised 1,143 restricted stock units (RSUs) on January 5, 2026, indicating continued confidence in the company's long-term prospects.
Patience also received an additional 5,443 RSUs and 6,354 stock options on January 2, 2026, suggesting the company's board is incentivizing him with additional equity-based compensation.

Filed: 2026-01-06

Hany Massarany, a director of Biodesix Inc, acquired 7,484 restricted stock units (RSUs) and 6,354 stock options on January 2, 2026, indicating insider confidence in the company's future.
The RSUs and stock options vest in four equal installments over 2026, which suggests Massarany's long-term commitment to the company.
The stock option grant has an exercise price of $6.46, which is lower than the company's current stock price, potentially allowing Massarany to profit from future stock price appreciation.

Filed: 2026-01-06

The reporting person, Lawrence T. Kennedy Jr., has acquired 5,443 restricted stock units (RSUs) and 6,354 stock options in BIODESIX INC (BDSX), indicating increased insider ownership and alignment with shareholder interests.
The RSUs and stock options vest in four equal installments over 2026, suggesting a long-term commitment to the company's performance.
The reporting person already owns a significant 10% stake in BIODESIX, further strengthening the alignment between management and shareholders.

Filed: 2026-01-06

Insider Jon Faiz Kayyem, a director of Biodesix Inc (BDSX), acquired 5,443 restricted stock units and 6,354 stock options on January 2, 2026, indicating his confidence in the company's future performance.
The vesting schedule of the restricted stock units and stock options, with four equal installments throughout 2026, suggests a long-term commitment from the director to the company's growth.
The strike price of $6.46 for the stock options indicates they were granted at-the-money, aligning the director's interests with those of other shareholders.

Filed: 2026-01-06

Gary Anthony Pestano, the Chief Development Officer of BIODESIX INC, has been granted 26,000 stock options with an exercise price of $6.46 per share. This indicates the company is incentivizing its key executive through equity-based compensation.
The stock options have a 10-year term and vest over a 4-year period, suggesting a long-term alignment of Pestano's interests with those of the company and its shareholders.
Insider transactions, such as this stock option grant, can provide insights into management's confidence in the company's future prospects and their commitment to driving shareholder value.

Filed: 2026-01-06

Kieran O'Kane, the Chief Commercial Officer of BIODESIX INC, has acquired 27,000 stock options exercisable at $6.46 per share, indicating potential confidence in the company's future performance.
The stock options vest over 48 months, suggesting a long-term commitment from the executive to the company's growth and development.
This transaction represents a direct increase in the executive's beneficial ownership of the company's common stock, which may signal positive expectations for the company's future prospects.

Filed: 2026-01-06

Scott Hutton, the President and CEO of BIODESIX INC, has acquired 97,000 stock options at an exercise price of $6.46 per share, indicating his confidence in the company's future performance.
The options granted to Hutton will vest in a series of 48 monthly installments, aligning his interests with long-term shareholders and promoting his continued leadership of the company.
This insider transaction suggests Hutton believes in the company's growth prospects and is willing to invest in BIODESIX INC's future, which could be a positive signal for investors.

Other reports for BIODESIX INC

Annual Report Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.